Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 6/20 | 0.50 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.45 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429053 | 1.00 | CCR3 (0.50) | CCR3SSTR3HTTCARM1PRMT6 | |
| SCHEMBL9460653 | 0.89 | CCR3 (0.52) | CCR3SSTR3HTTCARM1PRMT6 | |
| SCHEMBL8787759 | 0.89 | CCR3 (0.52) | CCR3SSTR3HTTCARM1PRMT6 | |
| SCHEMBL14368703 | 0.87 | CHRNA7 (0.51) | NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL14392352 | 0.87 | CHRNA7 (0.51) | NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL14392754 | 0.87 | CCR3 (0.48) | CCR3NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL14368724 | 0.87 | CCR3 (0.48) | CCR3NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL14368700 | 0.87 | CCR3 (0.48) | CCR3NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL14368669 | 0.87 | SSTR3 (0.55) | CCR3SSTR3NPC1RAB9A | |
| SCHEMBL27757345 | 0.87 | SSTR3 (0.55) | CCR3SSTR3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | CCR3 247/4885SSTR3 306/4885HTT 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.